Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is expected to report third quarter earnings results, before market open, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.98 per share.
Looking ahead, the full year loss are expected at $ 7.84 per share on the revenues of $ 6.96 million.
Previous Quarter Performance
Reata Pharmaceuticals, Inc. reported loss for the second quarter of $ 1.23 per share, from the revenue of $ 3.07 million. The consensus estimates are loss of $ 2.84 per share from $ 1.04 million in revenue. The bottom line results beat street analysts by $ 1.61 or 56.69 percent, at the same time, top line results outshined analysts by $ 2.03 million or 195.19 percent.
Stock Performance
On Friday, shares of Reata Pharmaceuticals, Inc. has traded high as $ 133.29 and has cracked $ 129.65 on the downward trend, reaching $ 131.89 with volume of 276.10 thousand shares.
According to the previous trading day, closing price of $ 131.89, representing a 45.50 % increase from the 52 week low of $ 88.17 and a 50.27 % decrease over the 52 week high of $ 257.97.
The company has a market capital of $ 4.43 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Reata Pharmaceuticals, Inc. will be hosting a conference call at 8:00 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.reatapharma.com
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreichs ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc.
